Medicinova MN-166-ALS-2301, COMBAT-ALS: Phase 2b/3, placebo-controlled trial of MN-166/Ibudilast in participants with Amylotrophic Lateral Sclerosis (ALS)
C
Cynthia Bodkin, MD
Primary Investigator
Recruiting
18 years - 80 years
All
Phase
2/3
10 participants needed
2 Locations
Brief description of study
Who is Eligible
- Ages 18-80
- Diagnosis of ALS with symptoms starting less than 18 months ago
- Able to swallow medication capsules
- No history of cancer within last 5 years
- No use of tracheostomy or almost continuous ventilator support
What is Invovled
- In-person appointments at the IUH Neuroscience Center
- Participants will take Ibudilast capsules twice daily for approximately 18 months of participation. Some telephone appointments available.
Compensation
- Compensation available via payment card for each completed appointment
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Amylotrophic Lateral Sclerosis,ALS
-
Age: 18 years - 80 years
-
Gender: All
Updated on
01 Aug 2024.
Study ID: 2001659563
Find a site
,
You have contacted , on
Your message has been sent to the study team at ,
A copy of the message has been sent to your email
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
Primary Contact
